By ipomarket.in Editorial Team · Last reviewed: 2026-10-19
Disclaimer: This article is for informational purposes only and does not constitute investment advice. IPO investments are subject to market risks. Please read the offer document carefully and consult a SEBI-registered investment advisor before investing.
Ask any group of retail investors what they look at before an IPO, and "GMP" will come up fast. Grey Market Premium has become shorthand for whether an issue is "hot" or not. But GMP tells you something quite narrow, and confusing it with business quality is one of the most common mistakes new IPO investors make. This piece separates the two clearly.
What GMP actually is
GMP is the premium at which IPO shares are informally traded above the issue price before the stock lists on the exchanges. This trading happens outside SEBI's regulatory framework. In other words, it is an unofficial, unregulated market with no legal backing and no guarantee behind it.
Because it sits outside regulation, GMP reflects market sentiment and demand, but it does not guarantee the actual listing price. It is a mood reading, not a price forecast. For a fuller primer, see our explainer on what IPO GMP is and how it works.
Why GMP is not a measure of business quality
This is the core distinction. GMP gives an indication of the short-term grey market vibe, not the quality of the business over the long run. The two can point in opposite directions.
A company with strong financials, a reasonable valuation and a well-structured offer might list at only a modest premium, or even at par. Meanwhile, a mediocre company riding hype could show an enormous GMP and then disappoint on listing day. Many IPOs that carried high GMP have listed flat or down. The excitement was real; the follow-through was not.
Business quality is a different test altogether. It asks whether the underlying company would still be worth owning even if the listing-day pop disappeared. That answer depends on revenue growth consistency, debt-to-equity ratio, profit margins and cash flow, none of which GMP captures.
The traps that make GMP misleading
There are three structural problems with leaning on GMP.
First, it can be manipulated. Grey market operators may artificially prop up a GMP without any genuine subscription depth behind it, especially when institutional (QIB) demand is weak despite a high quoted premium.
Second, it is volatile. A high GMP can move by double digits within a single week and has no obligation to reflect fundamentals. It can evaporate overnight.
Third, it has no predictive power beyond listing. GMP cannot tell you how a stock will perform three months, six months or a year after listing. Its appropriate role is as one very minor data point among many.
Absolute number versus percentage
When people do look at GMP, they often quote the rupee figure and stop there. The percentage premium usually gives better insight. A GMP of ₹40 on a ₹100 issue is a 40% premium. The same ₹40 GMP on a ₹600 issue is only about 6.7%. The headline number looks identical, but the signal is completely different. If you must track GMP, track it as a percentage of the issue price.
Read momentum, not a single snapshot
A single-day GMP figure is noise. GMP momentum, whether the premium is stable, rising or cooling over several days, can signal shifts in sentiment more meaningfully than one isolated reading. A premium that has held steady for multiple days carries more weight than one that spiked in the final 24 to 48 hours before listing, which can itself be a sign of manipulation.
Pair GMP with subscription, then question that too
The more reliable approach layers GMP on top of QIB subscription data. GMP alone is incomplete, and its true value emerges only when cross-referenced with live subscription figures. If a high GMP is accompanied by weak QIB participation, treat the premium with suspicion.
But subscription numbers come with their own caveat. High subscription multiples tell you how many people wanted shares, not whether the business earns its valuation. Oversubscription reflects strong demand for the shares on offer, not business quality. So you cross-check GMP against subscription, and then check both against fundamentals. Our guide to QIB, NII and retail subscription data explains how to read those categories.
When GMP deserves a little more trust
According to one broker framework, GMP is more trustworthy when several conditions line up: the IPO is from a large, well-known company with a track record, QIB subscription is 30x or higher, overall subscription is 50x or higher, market conditions have been stable, and the GMP has stayed consistently high for multiple days.
The same framework flags situations to treat sceptically: SME IPOs, low QIB subscription despite a high GMP, a market that has fallen sharply just before listing, a GMP that jumped suddenly in the last 24 to 48 hours, or a loss-making company. Even in the trustworthy scenarios, GMP remains a supporting signal, not the decision itself.
What actually drives a good IPO decision
The most reliable IPO analysis has little to do with the grey market. It involves reading the DRHP and RHP, evaluating financial health, comparing valuation with listed peers and assessing management quality. Our walkthrough on how to read a DRHP is a good starting point.
A sensible checklist puts business quality, valuation, financial trend, peer comparison, subscription quality and market context first, with GMP coming last. Concretely, an IPO decision should come from understanding the business, checking financial performance, evaluating a reasonable valuation against peers (using multiples such as P/E, P/B and EV/EBITDA), knowing how the proceeds will be used, and reading the risk factors in the offer documents.
It is worth remembering that SEBI has issued investor education circulars and warnings specifically mentioning the risks of grey market participation. The regulator's consistent message is that investment decisions should be based on the DRHP and Red Herring Prospectus, not on an unregulated premium.
Bottom line
GMP is a sentiment gauge from an unregulated market. Used well, it is one of many tools, best read as a percentage, tracked for momentum, and cross-checked against QIB subscription and company fundamentals. Used badly, as a standalone buy signal, it rewards hype and punishes investors when the premium evaporates. Business quality and GMP are not the same thing, and only one of them survives the first year after listing.
FAQ
Does a high GMP mean an IPO is a good investment?
No. GMP reflects short-term grey market sentiment, not the quality of the business. A mediocre company riding hype can show a large GMP and still list flat or down, while a strong company may list at a modest premium or at par. Business quality depends on revenue growth, margins, debt and cash flow, none of which GMP measures.
Should I look at the rupee GMP or the percentage?
The percentage usually gives better insight. A ₹40 GMP on a ₹100 issue is a 40% premium, but the same ₹40 on a ₹600 issue is only about 6.7%. The absolute number can be misleading on its own.
Can GMP be manipulated?
Yes. The grey market is unregulated, so operators can artificially prop up a GMP without genuine subscription depth, particularly when QIB demand is low despite a high quoted premium. A premium that jumps suddenly in the final 24 to 48 hours is a warning sign.
When is GMP relatively more reliable?
One broker framework suggests trusting GMP more when the issuer is a large, well-known company with a track record, QIB subscription is 30x or higher, overall subscription is 50x or higher, the market has been stable, and GMP has stayed high for several days. Even then, it is a supporting signal rather than the decision itself.
What should I rely on instead of GMP?
Read the DRHP and RHP, check financial performance, compare valuation with listed peers, review how the proceeds will be used, and assess management quality. Treat GMP as the last item on the checklist, not the first.
Last reviewed: 2026-10-19 by the ipomarket.in Editorial Team.